熱門資訊> 正文
强生将癫痫病候选人交给Addex，结束长达数十年的合作伙伴关系
2025-04-18 01:30
- Swiss biopharma Addex Therapeutics (NASDAQ:ADXN) announced Thursday that Johnson & Johnson (NYSE:JNJ) has returned all development and commercialization rights linked to its epilepsy candidate ADX71149, ending a more than 20-year-long partnership between the two firms.
- J&J’s decision comes nearly nine months after the company decided to discontinue the development of ADX71149 (JNJ-40411813) in epilepsy following a mid-stage trial setback for the small molecule therapy.
- The positive allosteric modulator (PAM) of metabotropic glutamate receptor-2 was developed as part of a collaboration between the Geneva-based company and J&J’s Janssen unit, launched in 2004.
- “ADX71149 is a high-quality asset which has completed three Phase 2 studies, so we are excited to regain control of its development from our partner with its high-quality data package and significant material,” CEO Tim Dyer said.
More on Addex Therapeutics, J&J, etc.
- Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript
- Johnson & Johnson 2025 Q1 - Results - Earnings Call Presentation
- Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves
- Short bets against S&P 500 healthcare stock rise in March; MRNA stays top shorted
- Barclays names most and least affected MedTech companies from tariffs
推薦文章
一周財經日曆丨降息信號將定？下周全球央行年會成關鍵；小米、泡泡瑪特、快手領銜港股財報潮
港股周報丨見證歷史！南向資金單日瘋狂買入港股359億港元；騰訊績后股價一度升破600港元
特朗普政府據悉考慮動用芯片法案資金來入股英特爾
美股機會日報丨「恐怖數據」符合預期，交易員下調美聯儲降息預期；巴菲特Q2新建倉股飆升，聯合健康盤前漲超10%
銀諾醫藥-B上市首日暴漲285%，一手賺超1萬港元
投資大佬Tepper減持阿里巴巴、京東等 買入股價暴跌的聯合健康
伯克希爾減持蘋果股份 增持聯合健康集團
8月15日外盤頭條：特朗普政府洽購英特爾股份 貝森特否認推動降息 蘋果重新設計Apple Watch血氧功能
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
